SPRB — SPRUCE BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1683553 ·
Last close
$51.81
Market Cap
$142.60M
52W High
$80.00
52W Low
$48.25
ADV30
78,066
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,987,000 | -12,266,000 | 56,166,000 | 54,080,000 | 21,518,000 |
| Dec 2025 | 0 | — | -11,100,000 | -14,646,000 | 53,021,000 | 48,906,000 | 10,505,000 |
| Sep 2025 | 0 | — | -8,229,000 | -8,212,000 | 15,313,000 | 10,669,000 | 9,927,000 |
| Jun 2025 | 0 | — | -2,692,000 | -2,067,000 | 21,820,000 | 16,387,000 | 8,640,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,327,000
Investing CF
$0
Financing CF
$43,481,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-57.82
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-289,234,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-38,876,000
Pretax Income TTM
$-38,966,000
Interest Exp TTM
$90,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -36,513,000 | -38,966,000 | 53,021,000 | 10,505,000 | — | -33,327,000 |
| Dec 2024 | 4,911,000 | -56,151,000 | -53,036,000 | 45,209,000 | 16,388,000 | — | -55,964,000 |
| Dec 2023 | 10,089,000 | -51,993,000 | -47,919,000 | 103,946,000 | 27,437,000 | — | -33,275,000 |
| Dec 2022 | 0 | -47,283,000 | -46,180,000 | 85,648,000 | 17,162,000 | — | -41,683,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KZIA | KAZIA THERAPEUTICS LTD | $142.95M | $12.51 | — |
| MSLE | Satellos Bioscience Inc. | $141.76M | $6.80 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $146.55M | $7.91 | — |
| EQ | Equillium, Inc. | $146.69M | $2.32 | — |
| CNTB | Connect Biopharma Holdings Ltd | $135.65M | $2.40 | — |
News headlines (Yahoo Finance, 1h cache)
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-13 12:00 · Yahoo
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
2026-05-04 12:00 · Yahoo
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2026-04-21 03:45 · Yahoo
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-04-20 20:01 · Yahoo
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade
2026-04-03 13:55 · Yahoo
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
2026-03-18 13:55 · Yahoo
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss
2026-03-17 23:59 · Yahoo
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-09 11:05 · Yahoo
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
2026-03-09 11:00 · Yahoo
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway
2026-03-04 05:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.